THROMBOGENICS

THROMBOGENICS

Previous company name

Name change date

Company Overview
ThromboGenics is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. ThromboGenics was founded by Professor Dйsirй Collen and the Katholieke Universiteit Leuven (KULeuven) (Belgium) in 1991.
ThromboGenic’s aims to be a leading biopharmaceutical company developing innovative therapies and products. The company’s goal is to become a leader in the development and commercialization of innovative drugs for the treatment of disorders of the vasculature.
The company has used its in house expertise to build a significant pipeline of promising drug candidates, a number of which are in clinical trials. The company is focused on developing new medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system. ThromboGenics’ lead product is microplasmin, a stable proteolytic enzyme which is in Phase II trials for eye disease and thrombotic disease.
The company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical trials. To leverage its expertise in the development and regulatory approval process, ThromboGenics selectively forms development and marketing collaborations with experienced partners in the pharmaceutical industry.
The company has research facilities located in Leuven, Belgium. It also has facilities in Ireland and the United States.
Business Summary
The Company is a biopharmaceutical company with a proprietary position in the development of drugs for conditions related to the blood vessel system. The Company has built a significant pipeline of drug programs, a number of which are in clinical trials.
Description and history
The Company is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in house expertise to build a significant pipeline of promising drug candidates, a number of which are in clinical trials. The Company is focused on developing new medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system. The Company’s lead product is microplasmin, a stable proteolytic enzyme which is in Phase II trials for eye disease and thrombotic disease.

The Company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical trials. To leverage its expertise in the development and regulatory approval process, ThromboGenics selectively forms development and marketing collaborations with experienced partners in the pharmaceutical industry. Such collaborations can lead to ThromboGenics generating revenues via milestone payments, as well as royalties on commercial sales.

The Company was founded by Professor Dйsirй Collen and the Katholieke Universiteit Leuven (KULeuven) (Belgium) in 1991. Since then it has developed a further important research relationship with the Flanders Interuniversity Institute for Biotechnology (VIB) (Belgium).

Professor Collen, ThromboGenics CEO, is a world-renowned expert in cardiovascular disease. His laboratory was the first to produce tissue plasminogen activator (tPA) for clinical use. tPA is the most successful thrombolytic agent for the treatment of acute myocardial infarction (heart attack), and has achieved annual peak sales in excess of $500 million. tPA was licensed to the leading US biotech company Genentech Inc. (part of Roche) and this agreement has generated significant royalty income.

2001 Completion of Phase II trial of staphylokinase for the treatment of acute myocardial infarction. In-licensing of microplasmin, nti-Factor VIII, PlGF, nti-PlGF, and nti-GPIb from VIB and/or KULeuven. Investment of approximately F .6 million by East Hill in the Company and acquisition of most of the outstanding shares in Thromb-X NV.

2002 Initiation of Phase I trial for microplasmin in systemic administration.

2003 Successful completion of Phase I trial for microplasmin in systemic administration. Positive pre-clinical results for microplasmin in ophthalmic indications. Opening of the US site in New York.

2004 Initiation of Phase IIa trial for microplasmin in ophthalmic indications. lliance with BioInvent to jointly develop antibody-based therapeutics. Licensing agreement with NuVue Technologies Inc for the development of plasmin-based drugs for visual disorders.
Collaboration agreement with Geymonat for the development of PlGF as a pro-angiogenic growth factor, for the treatment of ischemic diseases and tissue regeneration. In-licensing of nti-VP C from KULeuven.

2005 Initiation of Phase IIa trial for microplasmin in vascular indications. Initiation validation of full cGMP manufacturing for Phase III and commercial production of microplasmin.

2006 Licensing of PlGF for diagnostic applications to Biosite and another undisclosed diagnostic Company with Geymonat.

On 7 June 006 the Issuers extraordinary shareholders’ meeting decided to increase the Issuer’s share capital by way of the contribution in Kind of the shares in the Company on a share-for-share basis. The shares in the Company will be contributed at a value per share equal to the final Offer Price. Consequently, immediately after termination of the book-building procedure, the Issuer’s board of directors will establish the final Offer Price and thus the value of the contributed shares. s the condition precedent is fulfilled, they will then establish the Contribution in Kind and the amount of the increase of the Issuer’s capital and they will issue the shares to the shareholders of the Company who contributed their shares in the Company to the Issuer.

ThromboGenics was founded by Professor Dйsirй Collen and the Katholieke Universiteit Leuven

Business Line
Focused on the development of therapeutics for conditions related to the vascular system
Subsidiary

Advisor
KPMG BEDRIJFSREVISOREN
IPO date
7/7/2006
US SIC Code
2834
Company Address
Gaston Geenslaan 1

City province or state postal code
3001, HEVERLEE
Phone: +32 16 75 13 10
Fax: +32 16 75 13 11
Country address: BELGIUM
Website url: www.thrombogenics.com